Lansoprazole | St. Mary's Medical Park Pharmacy Breastfeeding

Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Lansoprazole | St. Mary's Medical Park Pharmacy while breastfeeding. We will also discuss about common side effects and warnings associated with Lansoprazole | St. Mary's Medical Park Pharmacy.

What is Lansoprazole | St. Mary's Medical Park Pharmacy used for?


Lansoprazole delayed-release capsules are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults. ( 1.1) Eradication of H.pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2) Maintenance of healed duodenal ulcers in adults. ( 1.3) Treatment of active benign gastric ulcer in adults. ( 1.4) Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5) Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8) Maintenance of healing of EE in adults. ( 1.9) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [ see Clinical Studies ( 14.1) ]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated I adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, Microbiology section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2) ]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole delayed-release capsules are indicated in adults to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [ see Clinical Studies ( 14.3) ]. 1.4 Treatment of Active Benign Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer [ see Clinical Studies ( 14.4) ]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond eight weeks [ see Clinical Studies ( 14.5) ]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [ see Clinical Studies ( 14.6) ]. 1.7 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Lansoprazole delayed-release capsules are indicated in adults and pediatric patients one year of age and older for the treatment of heartburn and other symptoms associated with GERD for up to eight weeks [ see Clinical Studies ( 14.7) ]. 1.8 Treatment of Erosive Esophagitis (EE) Lansoprazole delayed-release capsules are indicated for short-term treatment for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for healing and symptom relief of all grades of EE. For adults who do not heal with Lansoprazole for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis an additional eight week course of Lansoprazole may be considered [see Clinical Studies ( 14.8) ]. 1.9 Maintenance of Healing of EE Lansoprazole delayed-release capsules are indicated in adults to maintain healing of EE. Controlled studies did not extend beyond 12 months [ see Clinical Studies ( 14.9) ]. 1.10 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole delayed-release capsules are indicated in adults for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [ see Clinical Studies ( 14.10) ].

Is using Lansoprazole | St. Mary's Medical Park Pharmacy unsafe in breastfeeding? Can there be bad consequences for baby if I use it while breastfeeding?

Lansoprazole | St. Mary's Medical Park Pharmacy safe for breastfeeding
Active ingredient in Lansoprazole | St. Mary's Medical Park Pharmacy is Lansoprazole and based on our analysis of Lansoprazole it appears that using Lansoprazole | St. Mary's Medical Park Pharmacy is safe in breastfeeding. Below is analysis of Lansoprazole while breastfeeding.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, taking into account the importance of lansoprazole to the mother.

Lansoprazole | St. Mary's Medical Park Pharmacy Breastfeeding Analsys


Lansoprazole while Breastfeeding

Safe

CAS Number: 103577-45-3

At latest update, relevant information on excretion into breast milk was not found. Due to a high serum-protein-binding capacity, excretion of Lansoprazole into breast milk is non-significant. Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food. Both Omeprazole and Pantoprazole pertain to the same chemical group with similar pharmacokinetics that are excreted in non-significant amount into the breast milk. Medication that has been used for treatment of newborn and premature infants. Hyperprolactinemia and galactorrhea have been reported by the use of such medication, though some authors have failed to show the same findings.


Lansoprazole | St. Mary's Medical Park Pharmacy Breastfeeding Analsys - 2


Lansoprazole while Breastfeeding

CAS Number: 103577-45-3

No information is available on the use of lansoprazole during breastfeeding. However, lansoprazole has been used safely in newborn infants, so it is unlikely that the amount in breastmilk would be harmful.



What should I do if already breastfed my kid after using Lansoprazole | St. Mary's Medical Park Pharmacy?

Lansoprazole | St. Mary's Medical Park Pharmacy is safe in breastfeeding and should not create any health problem for your baby but in case you feel any health issue associated with Lansoprazole | St. Mary's Medical Park Pharmacy you should contact your doctor or health care provider. Be it pregnancy or lactation you shall keep your doctor informed.


My health care provider has asked me to use Lansoprazole | St. Mary's Medical Park Pharmacy, what to do?

Usage of Lansoprazole | St. Mary's Medical Park Pharmacy is safe for nursing mothers and baby, No worries.


If I am using Lansoprazole | St. Mary's Medical Park Pharmacy, will my baby need extra monitoring?

No


Who can I talk to if I have questions about usage of Lansoprazole | St. Mary's Medical Park Pharmacy in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week